Expression and role of VEGFA and miR‑381 in portal vein tumor thrombi in patients with hepatocellular carcinoma

Wang,Jing; Wu,Shuzhi; Huang,Tianren

doi:10.3892/etm.2018.6129

Expression and role of VEGFA and miR‑381 in portal vein tumor thrombi in patients with hepatocellular carcinoma

Authors:
- Jing Wang
- Shuzhi Wu
- Tianren Huang
View Affiliations

Affiliations: Experimental Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Institute for Viral Disease Control and Prevention, Shandong Center for Disease Control and Prevention, Jinan, Shandong 250014, P.R. China
Published online on: May 3, 2018 https://doi.org/10.3892/etm.2018.6129
Pages: 5450-5456

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to examine the expression and role of vascular endothelial growth factor A (VEGFA) and microRNA (miRNA or miR)‑381 in tumor thrombi from patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT). Tumor thrombi and adjacent paired tissues were collected from 39 patients with hepatocellular carcinoma with PVTT. VEGFA expression levels were assessed using reverse transcription‑quantitative polymerase chain reaction and western blotting. miRNAs that may regulate VEGFA expression were predicted using bioinformatics analysis and confirmed via a dual luciferase reporter assay. The effects of VEGFA and its upstream miRNA on proliferation of the proliferation of EAhy926 human venous endothelial cells were analyzed using an MTT assay. Compared with the paired adjacent tissues, VEGFA was significantly upregulated at both the mRNA and protein level in tumor thrombi (P<0.05). VEGFA was predicted to be a target of miR‑381 and this was confirmed experimentally. miR‑381 expression was significantly downregulated in tumor thrombi from patients with PVTT compared with paired adjacent tissues (P<0.05). In addition, transfection with antagomirs against miR‑381 or short interfering RNA against VEGFA significantly inhibited EAhy926 cell proliferation (P<0.05). In conclusion, the results of the present study indicate that VEGFA is upregulated in tumor thrombi whereas miR‑381 is downregulated. VEGFA is regulated by miR‑381 and both may be associated with the development of PVTT.

View Figures

View References

1	Wedd JP, Nordstrom E, Nydam T, Durham J, Zimmerman M, Johnson T, Purcell Thomas W and Biggins SW: Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient. Liver Transpl. 21:1543–1552. 2015. View Article : Google Scholar : PubMed/NCBI
2	Kuszyk BS, Beauchamp NJ Jr and Fishman EK: Neurovascular applications of CT angiography. Semin Ultrasound CT MR. 19:394–404. 1998. View Article : Google Scholar : PubMed/NCBI
3	Kanda M, Sugimoto H and Kodera Y: Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 21:10584–10597. 2015. View Article : Google Scholar : PubMed/NCBI
4	Trousseau Armand: Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris. Translated and edited with notes and appendices by P. Victor Bazire. Med Clin. 1:1801–1867. 1872.
5	Thodiyil PA and Kakkar AK: Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 87:1076–1077. 2002. View Article : Google Scholar : PubMed/NCBI
6	Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ and Rosendaal FR: Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: Results of a record linkage study. J Thromb Haemost. 4:529–535. 2006. View Article : Google Scholar : PubMed/NCBI
7	Folkman J: What is the evidence that tumors are angiogenesis dependent? J National Cancer Institute. 82:4–7. 1990. View Article : Google Scholar
8	Cosmai L, Gallieni M, Liguigli W and Porta C: Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). J Nephroll. 30:171–180. 2017. View Article : Google Scholar
9	Wu L, Zhang YS, Ye ML, Shen F, Liu W, Hu HS, Li SW, Wu HW, Chen QH and Zhou WB: Overexpression and correlation of HIF-2α, VEGFA and EphA2 in residual hepatocellular carcinoma following high-intensity focused ultrasound treatment: Implications for tumor recurrence and progression. Exp Ther Med. 13:3529–3534. 2017. View Article : Google Scholar : PubMed/NCBI
10	Rong W, Yang L, Yin L, Gao Y, Xiao T and Cheng S: PSG9 promotes angiogenesis by stimulating VEGFA production and is associated with poor prognosis in hepatocellular carcinoma. Sci China Life Sci. 60:528–535. 2017. View Article : Google Scholar : PubMed/NCBI
11	Ghosh A, Dasgupta D, Ghosh A, Roychoudhury S, Kumar D, Gorain M, Butti R, Datta S, Agarwal S, Gupta S, et al: miRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2. Cell Death Dis. 8:e27062017. View Article : Google Scholar : PubMed/NCBI
12	Hsu CH, Kang YK, Yang TS, Shun CT, Shao YY, Su WC, Su WC, Sandoval-Tan J, Chiou TJ, Jin K, et al: Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study. Oncology. 85:44–52. 2013. View Article : Google Scholar : PubMed/NCBI
13	Meyer G: Venous thromboembolism and cancer. Rev Prat. 65:216–219. 2015.(In French). PubMed/NCBI
14	Bianconi D, Schuler A, Pausz C, Geroldinger A, Kaider A, Lenz HJ, Kornek G, Scheithauer W, Zielinski CC, Pabinger I, et al: Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. Thromb Res. 136:865–869. 2015. View Article : Google Scholar : PubMed/NCBI
15	Kokudo T, Hasegawa K and Kokudo N: Liver, pancreas, biliary tract cancer. I. Surgical treatment of hepatocellular carcinoma associated with vascular tumor thrombosis. Gan To Kagaku Ryoho. 41:1209–1211. 2014.(In Japanese). PubMed/NCBI
16	Posch F, Thaler J, Zlabinger GJ, Königsbrügge O, Koder S, Zielinski C, Pabinger I and Ay C: Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: Results from the Vienna cancer and thrombosis study (CATS). Clin Cancer Res. 22:200–206. 2016. View Article : Google Scholar : PubMed/NCBI
17	Babu Govind K and Bhat GR: Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 10:6492016. View Article : Google Scholar : PubMed/NCBI
18	Evans CE, Grover SP, Saha P, Humphries J, Kim JW, Modarai B and Smith A: Suppression of angiogenic response in local vein wall is associated with reduced thrombus resolution. Thromb Res. 134:682–685. 2014. View Article : Google Scholar : PubMed/NCBI
19	Di Vito C, Navone SE, Marfia G, Hadi Abdel L, Mancuso ME, Pecci A, Crisà FM, Berno V, Rampini P, Campanella R and Riboni L: Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release. Platelets. 28:585–594. 2017. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
22	Yang BH, Xia JL, Huang LW, Tang ZY, Chen MS, Li JQ, Liang AM, Mo QG, Lu HS, Dai CL, et al: Changes of clinical aspect of primary liver cancer in China during the past 30 years-control study for 3,250 cases with primary liver cancer. Zhonghua Yi Xue Za Zhi. 83:1053–1057. 2003.(In Chinese). PubMed/NCBI
23	Karnes RJ and Blute ML: Surgery insight: Management of renal cell carcinoma with associated inferior vena cava thrombus. Nat Clin Pract Urol. 5:329–339. 2008.PubMed/NCBI
24	Lambert EH, Pierorazio PM, Shabsigh A, Olsson CA, Benson MC and McKiernan JM: Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. Urology. 69:1054–1058. 2007. View Article : Google Scholar : PubMed/NCBI
25	Lam JS, Klatte T, Kim HL, Patard JJ, Breda A, Zisman A, Pantuck AJ and Figlin RA: Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol. 65:235–262. 2008. View Article : Google Scholar : PubMed/NCBI
26	Squillaci E, Fanucci E, Sciuto F, Masala S, Sodani G, Carlani M and Simonetti G: Vascular involvement in pancreatic neoplasm: A comparison between spiral CT and DSA. Dig Dis Sci. 48:449–458. 2003. View Article : Google Scholar : PubMed/NCBI
27	Chow LC and Rubin GD: CT angiography of the arterial system. Radiol Clin North Am. 40:729–749. 2002. View Article : Google Scholar : PubMed/NCBI
28	Hakenberg OW: Comment on Di Silverio et al: Neodajuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int. 80:4542008. View Article : Google Scholar : PubMed/NCBI
29	Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ and Belldegrun AS: Neoadjuvant targeted therapy and advanced kidney cancer: Observations and implications for a new treatment paradigm. BJU Int. 102:692–696. 2008. View Article : Google Scholar : PubMed/NCBI
30	Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ and Perrotte P: Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol. 53:845–848. 2008. View Article : Google Scholar : PubMed/NCBI
31	Harshman LC, Srinivas S, Kamaya A and Chung BI: Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol. 6:338–343. 2009. View Article : Google Scholar : PubMed/NCBI
32	Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E and Haanen JB: Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol. 49:520–523. 2010. View Article : Google Scholar : PubMed/NCBI
33	Roberts E, Cossigny DA and Quan GM: The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer. 2013:4183402013. View Article : Google Scholar : PubMed/NCBI
34	Yan JJ, Zhang YN, Liao JZ, Ke KP, Chang Y, Li PY, Wang M, Lin JS and He XX: miR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1. Oncotarget. 6:29527–29542. 2015. View Article : Google Scholar : PubMed/NCBI
35	Zhao X, Mohan R, Özcan S and Tang X: MicroRNA-30d induces insulin transcription factor MafA and insulin production by targeting mitogen-activated protein 4 kinase 4 (MAP4K4) in pancreatic β-cells. J Biol Chem. 287:31155–31164. 2012. View Article : Google Scholar : PubMed/NCBI
36	Chen K and Rajewsky N: The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 8:93–103. 2007. View Article : Google Scholar : PubMed/NCBI
37	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
38	Tsai HC, Tzeng HE, Huang CY, Huang YL, Tsai CH, Wang SW, Wang PC, Chang AC, Fong YC and Tang CH: WISP-1 positively regulates angiogenesis by controlling VEGF-A expression in human osteosarcoma. Cell Death Dis. 8:e27502017. View Article : Google Scholar : PubMed/NCBI
39	Liang Y, Zhao Q, Fan L, Zhang Z, Tan B, Liu Y and Li Y: Down-regulation of MicroRNA-381 promotes cell proliferation and invasion in colon cancer through up-regulation of LRH-1. Biomed Pharmacother. 75:137–141. 2015. View Article : Google Scholar : PubMed/NCBI
40	Liang HQ, Wang RJ, Diao CF, Li JW, Su JL and Zhang S: The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. Oncotarget. 6:29413–29427. 2015. View Article : Google Scholar : PubMed/NCBI
41	Xu Y, Ohms SJ, Li Z, Wang Q, Gong G, Hu Y, Mao Z, Shannon MF and Fan JY: Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance. PLoS One. 8:e820622013. View Article : Google Scholar : PubMed/NCBI
42	Chen B, Duan L, Yin G, Tan J and Jiang X: Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells-Cdc2 activity is up-regulated by targeting WEE1. Clinics (Sao Paulo). 68:825–833. 2013. View Article : Google Scholar : PubMed/NCBI
43	Rothschild SI, Tschan MP, Jaggi R, Fey MF, Gugger M and Gautschi O: MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma. J Thoracic Oncol. 7:1069–1077. 2012. View Article : Google Scholar
44	Wu L, Zheng J, Chen P, Liu Q and Yuan Y: Small nucleolar RNA ACA11 promotes proliferation, migration and invasion in hepatocellular carcinoma by targeting the PI3K/AKT signaling pathway. Biomed Pharmacother. 90:705–712. 2017. View Article : Google Scholar : PubMed/NCBI
45	Hou G, Liu G, Yang Y, Li Y, Yuan S, Zhao L, Wu M, Liu L and Zhou W: Neuraminidase 1 (NEU1) promotes proliferation and migration as a diagnostic and prognostic biomarker of hepatocellular carcinoma. Oncotarget. 7:64957–64966. 2016. View Article : Google Scholar : PubMed/NCBI
46	Tang Y, Yu H, Zhang L, Wang K, Guo W, Shi J, Liu S, Wu M, Wang H and Cheng S: Experimental study on enhancement of the metastatic potential of portal vein tumor thrombus-originated hepatocellular carcinoma cells using portal vein serum. Chin J Cancer Res. 26:588–595. 2014.PubMed/NCBI